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Evidence for impaired assimilation of protein in chronic renal
failure.
Background. Protein malnutrition is a common finding in
chronic renal failure (CRF) and is associated with poor out-
come. We hypothesized that besides inadequate dietary pro-
tein intake and alterations in metabolism, deficient protein as-
similation (digestion and absorption) might contribute to the
pathogenesis of protein malnutrition in uremia.
Methods. Protein assimilation was evaluated in 64 healthy
volunteers and 119 CRF patients by means of a 13C protein
breath test and/or quantification of p-cresol in a 24-hour urine
collection. Both approaches provide reliable information on
the efficiency of protein assimilation. Breath test results were
expressed as maximum percentage of administered dose of
13C (%max) and cumulative percentage at the end of the test
(%cumend). Data were stratified according to renal function.
Results. As compared to subjects with glomerular filtration
rate (GFR) ≥ 60 mL/min/1.73 m2, subjects with GFR < 30 mL/
min/1.73 m2 demonstrated significantly lower breath test–
derived parameters of protein assimilation (%max 3.97 ± 0.23 vs.
5.20 ± 0.23, P = 0.0017; %cumend 13.91 ± 0.86 vs. 17.40 ± 0.80,
P = 0.013) and significantly higher urinary output of p-cresol
(54.88 mg/24 hours vs. 28.65 mg/24 hours, P = 0.0005). %max
(r = 0.399, P < 0.0001), %cumend (r = 0.347, P = 0.0007), and
urinary p-cresol (r = −0.229, P = 0.007) correlated significantly
with GFR. Serum albumin correlated significantly with %max
(r = 0.399, P = 0.0002), %cumend (r = 0.408, P = 0.0001), and
urinary p-cresol output (r = −0.186, P = 0.035).
Conclusion. Our data provide evidence that protein assimi-
lation is impaired in CRF. This impairment might contribute to
protein malnutrition in CRF.
Protein malnutrition is a common finding in patients
with chronic renal failure (CRF). Prevalences up to 65%
have been reported in patients with end-stage renal dis-
ease (ESRD) [1–6]. Considerable evidence has accumu-
lated over the last decade suggesting that malnutrition in
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uremic patients is associated with poor outcome [7–9].
A strong association has been demonstrated between
malnutrition, inflammation, and atherosclerosis, which is
a major cause of morbidity and mortality in advanced
CRF [3, 6].
Theoretically, protein malnutrition may result from (1)
inadequate dietary protein intake, (2) impaired small in-
testinal protein assimilation (digestion and absorption),
(3) increased protein losses, and/or (4) alterations in pro-
tein metabolism. To date, most researchers have focused
on the impact of disturbances of metabolism. Metabolic
acidosis, a frequent complication of uremia, has been
shown to induce net protein catabolism by several mech-
anisms [10–12]. High circulating levels of inflammatory
cytokines, as seen in CRF patients [13–15], have been
demonstrated to stimulate muscle protein breakdown
[16]. Finally, loss of muscle protein in uremia may be
related to impaired action of anabolic hormones such as
insulin.
Small intestinal assimilation of dietary protein, pro-
viding essential and nonessential amino acids for protein
synthesis, plays a pivotal role in the maintenance of to-
tal body nitrogen balance. Information on the efficiency
of protein assimilation in uremia is limited, most prob-
ably due to the lack of an easy and reliable measuring
technique [17, 18]. Recently, the availability of protein,
highly enriched with 13C, has enabled breath test tech-
nology to be adapted for the study of protein assimila-
tion [19]. Breath tests are simple, easily repeatable, and
noninvasive. Hence, they are very suitable for performing
studies on a large scale, both in healthy volunteers and
in patients. Finally, they are very interesting as a func-
tional test because the obtained information represents
a dynamic evaluation rather than a static observation.
Protein escaping digestion and absorption in the small
intestine is intensely metabolized by the microbial flora
of the colon. Quantitatively, p-cresol is one of the most
important phenolic compounds recovered in feces and
urine [20]. It is a specific bacterial fermentation metabo-
lite of the amino acid tyrosine. Phenolic compounds that
are not used for bacterial protein synthesis are largely
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absorbed from the colonic lumen, detoxified, and urinar-
ily excreted [20, 21]. Urinary output of p-cresol has been
demonstrated to reflect the amount of protein escaping
small intestinal digestion and absorption [21] and thus
may represent an indirect parameter of the efficiency of
protein assimilation.
The aim of the present study was to evaluate whether
protein assimilation is impaired in patients with renal fail-
ure. We therefore studied a large cohort of patients and
healthy volunteers with varying glomerular filtration rate
(GFR) by means of breath test technology and quantifi-
cation of urinary p-cresol output.
METHODS
Subjects
Sixty-four volunteers and 119 patients with CRF were
included. The volunteers comprised members of the nurs-
ing and laboratory staff, medical students, and mem-
bers of an association of retired persons. All volunteers
claimed to be “healthy,” which was confirmed by a medi-
cal history taken by a physician (B.B.). None of them was
known to have renal disease or impaired renal function.
No metabolic, cardiovascular, gastrointestinal, or respi-
ratory disease was present. The patients were recruited
from the outpatient nephrology clinic. The causes of re-
nal failure included polycystic kidney disease (N = 16),
glomerular disease (N = 56), tubulointerstitial disease
(N = 20), vascular disease (N = 3), and unknown etiolo-
gies (N = 24). The study was approved by the Ethical
Committee of the University Hospital Gasthuisberg and
informed consent was obtained from all subjects.
Study design
Protein assimilation was evaluated in a cross-sectional
observational design by means of breath test technology
and/or quantification of urinary p-cresol output.
13C breath test studies
Eighty-four subjects (54 healthy volunteers and 30
CRF patients) were included in this part of the study.
None of them (1) had a history of gastrointestinal disease
or surgery, hepatic disease or diabetes mellitus, (2) used
drugs known to influence gastrointestinal motility (proki-
netics or antiemetics) or protein assimilation (prebiotics,
probiotics, antibiotics, or inhibitors of gastric acid secre-
tion) during the preceding 3 months, (3) or had metabolic
acidosis as defined by a serum bicarbonate of 20 mEq/L
or less.
13C protein breath test. Protein assimilation was evalu-
ated after an overnight fast of at least 12 hours by means of
a 13C protein breath test. The solid test meal (being a pan-
cake) consisted of 7.5 g of lyophilized 13C-leucine–labeled
egg white, 17.2 g of lyophilized 13C-leucine–labeled egg
yolk, 3.75 g of lyophilized unlabelled egg white, 3 g of
milk powder, 7 g of sugar, 17 g of flour, 130 mL of
water, and 5 g of butter. The methodology for obtain-
ing large amounts of egg proteins intrinsically labeled
with 13C has been described elsewhere [22]. The caloric
content of the meal amounted to 327.4 kcal (18.67 g
of protein, 6.15 g of fat, and 26.8 g of carbohydrates).
Subjects were asked to consume the meal together with
200 mL of water within 15 minutes. Breath samples for
the detection of 13CO2 were collected twice immediately
before the test meal and at 15-minute intervals for a
period of 6 hours thereafter.
13C-leucine breath test. The absorption and the oxida-
tive metabolism of leucine were evaluated in an unse-
lected subgroup of 17 subjects (seven healthy volunteers
and ten CRF patients). After an overnight fast of at least
12 hours, a single-lumen duodenal tube was positioned
in the second part of the duodenum under gastroscopic
control. Two hundred milligrams of 13C-leucine (99 MP)
dissolved in 20 mL of water was administered as a bolus
through the tube. Immediately after instillation, the tube
was removed. Breath samples for the detection of 13CO2
were collected twice immediately before the administra-
tion of the label and thereafter every 5 minutes during
the first hour and every 15 minutes for the following
3 hours.
Sampling, analytic procedures, and calculations.
Breath was collected by blowing air through a straw
in a small tube, called an exetainer (Europa Scientific,
Crewe, UK). The 13C content of the breath was de-
termined by on-line gas chromatographic purification-
isotope ratio mass spectometry (IRMS) (ABCA)
(Europa Scientific, Crewe, UK). The d values given by
the IRMS were converted to percentage 13C recovery per
hour (%dose/hour) of the initial amount administered ac-
cording to calculations described in detail by Ghoos et al
[23]. Cumulative percentages of label recovery (%cum)
were calculated by means of the trapezoidal rule. From
these data, the following parameters of protein assimi-
lation were derived: the maximum percentage of admin-
istered dose of 13C excreted per hour (%max) and the
cumulative percentage of 13C administered dose
recovered in breath at the end of the test (%cumend).
Urinary output of p-cresol
One hundred and twenty-two subjects (34 healthy vol-
unteers and 88 CRF patients) performed a 24-hour urine
collection. The collection bottles were refrigerated (0 to
4◦C) at the participant’s home to prevent bacterial growth
and brought to the laboratory within hours of termina-
tion of the collection. After measurement of the volume,
samples were taken and stored at –80◦C until analysis.
p-Cresol was analyzed by gas chromatography-mass
spectrometry (GC-MS) technology. The pH of 950 lL
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of urine sample was adjusted to pH 1 with concentrated
H2SO4 and the solution was heated to 90◦C for 30 min-
utes. After a cooling down period to ambient tempera-
ture, 50 lL 2,6-dimethylphenol solution (20 mg/100 mL)
was added as internal standard. One milliliter ethyl ac-
etate was added for the extraction of p-cresol. The solu-
tion was well mixed during 30 seconds and centrifuged
at 3300 rpm for 20 minutes. Five hundred microliters of
the supernatant was dried over anhydrous sodium sul-
fate. One hundred microliters of the resultant sample was
transferred to the GC-MS (Trace GC-MS) (Thermofinni-
gan, San Jose´, CA, USA) for automatic splitless injec-
tion of 0.5 lL. The analytical column used was a 30 m ×
0.32 mm internal diameter, film thickness 1 lm AT5-MS
(Alltech, Deerfield, IL, USA). Helium GC grade was
used as a carrier gas with a constant flow of 1.3 mL/min.
The oven was programmed from 75◦C (isotherm for
5 minutes) to 280◦C with 15◦C per minute. After sepa-
ration, p-cresol was identified by MS (Electron Impact
full scan mode from m/z 59 to m/z 590 at 2 scan/second).
Quantitative results were obtained by the internal stan-
dard method. Results were calculated as concentrations
(mg/L) and data were expressed as amounts excreted per
24 hours. To normalize for differences in dietary protein
intake, results were also expressed as the ratio of urinary
p-cresol to urinary urea nitrogen according to the follow-
ing equation:
Urinary p-cresol/urea nitrogen ratio
= urinary p-cresol (mg/24 h)urinary urea nitrogen (g/24 h)
Assuming no changes in serum urea nitrogen and body
weight over a 24-hour period in stable nondialyzed CRF
patients, urinary urea nitrogen can be used as a parameter
for protein intake [24].
Anthropometrics and biochemical analyses
Body mass index (BMI) was calculated from measured
height and body weight (kg/m2). Serum albumin, serum
bicarbonate, serum creatinine, and serum and urinary
urea nitrogen concentrations were measured using stan-
dard laboratory techniques. GFR was estimated by the
Cockcroft and Gault formula. Values were normalized for
body surface area (BSA) by multiplying with 1.73/BSA
(m2) and were expressed as mL/min/1.73 m2. BSA was
calculated from the formula of Haycock, Schwartz, and
Wisotsky [25]:
BSA(m2) = 0.024265 × weight (kg)0.5378
× height (cm)0.3964
For comparative purposes subjects were categorized into
three groups according to GFR: group A (GFR ≥ 60 mL/
min/1.73 m2), group B (GFR 59 to 30 mL/min/1.73 m2),
and group C (GFR < 30 mL/min/1.73 m2).
Statistical analysis
Data are expressed as mean ± SEM if normally
distributed or as median and range otherwise. Nor-
mality of distributions was assessed by Kolmogorov-
Smirnov and Cramer-von Mises test. In the figures, 95%
confidence intervals of the data are indicated where
appropriate.
Differences in measured and calculated data between
more than two subject groups were evaluated using para-
metric one-way analysis of variance (ANOVA) or the
Kruskal-Wallis test, followed by Bonferroni corrected
post hoc analysis for pair-wise comparisons. In two sam-
ple analyses unpaired Student t tests or Mann-Whitney
U tests were used. Pearson correlation coefficients were
calculated to assess possible associations between 13C
protein breath test results, urinary output of p-cresol
and urea nitrogen, age, serum albumin, BMI, and re-
nal function. P values less than 0.05 were considered
significant. The SAS version 8.02 (SAS Institute, Cary,




Demographics and nutrition. Subjects with GFR ≥
60 mL/min/1.73 m2 (group A) were significantly younger
than subjects with GFR < 60 mL/min/1.73 m2 (groups
B and C). Genders were equally distributed among the
different groups. A lower serum albumin was seen in sub-
jects with GFR < 30 mL/min/1.73 m2. Statistical signifi-
cance, however, was not reached (Table 1).
Breath test data. The mean 13CO2 excretion curves,
expressed as %dose/hour and %cum of the administered
dose obtained after ingestion of the 13C protein test meal
are depicted in Figure 1. The curves in the subjects with
GFR < 30 mL/min/1.73 m2 (group C) are flattened as
compared to those observed in subjects with GFR ≥
60 mL/min/1.73 m2 (group A). Breath test derived pa-
rameters of protein assimilation were significantly lower
in group C as compared to group A (%max 3.97 ± 0.23 vs.
5.20 ± 0.23, P = 0.0017; %cumend 13.91 ± 0.86 vs. 17.40 ±
0.80, P = 0.013) (Table 1). The differences remained sig-
nificant after stratification for age (%max 4.02 ± 0.25 vs.
5.71 ± 0.70, P = 0.014; %cumend 14.01 ± 0.93 vs. 19.94 ±
2.52, P = 0.017).
The mean 13CO2 excretion curves, expressed as
%dose/hour and %cum of the administered dose ob-
tained after intraduodenal instillation of 13C-leucine in
groups A and C are depicted in Figure 2. The curves are
almost identical in both groups. There were no differences
in breath test derived parameters (%max 7.80 ± 0.84 vs.
7.49 ± 0.52, P = 0.78; %cumend 14.69 ± 1.27 vs. 13.44 ±
1.17, P = 0.50) (Table 1).
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Table 1. 13C breath test studies
Group A Group B Group C
(GFR ≥ 60 mL/min/1.73 m2) (GFR 59 to 30 mL/min/1.73 m2) (GFR < 30 mL/min/1.73 m2)
Number 46 8 30
Age years 23 (18–70) 71 (59–78)a 55 (33–74)a,b
Male/female 23/23 4/4 17/13
Body weight kg 66.0 (47.0–116.0) 76.2 (54.5–87.5) 67.65 (44.1–101.6)
Body mass index kg/m2 21.48 (17.96–33.62) 25.83 (21.98–28.23)a 23.77 (15.55–32.55)
Bicarbonate mEq/L 23.55 ± 0.28 24.08 ± 0.71 24.71 ± 0.71
Serum urea nitrogen mg/dL 25.0 (14.0–42.0) 33.5 (25.0–41.0) 170.0 (65.0–255.0)a,b
Serum creatinine mg/dL 0.92 (0.73–1.19) 1.09 (1 00–1.45) 5.93 (1.78–10.61)a,b
Glomerular filtration rate mL/min/1.73 m2 102.78 (60.36–173.31) 56.98 (46.11–58.74)a 12.85 (6.79–29.78)a
Serum albumin g/L 41.35 (28.80–46.30) 41.75 (37.40–43.90) 40.30 (33.10–51.07)
Urinary urea nitrogen g/24 hours 19.9 (9.34–36.05) (N = 26) 14.65 (9.3–21.3) (N = 8) 16.0 (5.1–22.8) (N = 19)
13C protein breath test
%max 5.20 ± 0.23 4.73 ± 0.32 3.97 ± 0.23a
%cumend 17.40 ± 0.80 16.72 ± 0.82 13.91 ± 0.86a
13C-leucine breath test
%max 7.49 ± 0.52 (N = 7) — 7.80 ± 0.84 (N = 10)
%cumend 13.44 ± 1.17 (N = 7) — 14.69 ± 1.27 (N = 10)
Data are expressed as mean ± SEM if normally distributed or as median and range otherwise. Differences between groups were evaluated by one-way analysis of
variance/unpaired Student t test or Kruskal-Wallis test where appropriate, followed by post hoc pair-wise comparisons.






















Fig. 1. 13CO2 excretion curves of the 13C pro-
tein breath test expressed as %dose/hour (A)
and %cum (B). Mean values and 95% con-
fidence intervals are illustrated. Symbols are:





















Fig. 2. 13CO2 excretion curves of the 13C-
leucine breath test expressed as %dose/hour
(A) and %cum (B). Mean values and 95%
confidence intervals are illustrated. Symbols
are: () group A; () group C.
Urinary output of p-cresol
Demographics and nutrition. Subjects with GFR ≥
60 mL/min/1.73 m2 (group A) were significantly younger
than subjects with GFR < 60 mL/min/1.73 m2 (groups
B and C). There were no statistical differences in gen-
der distribution among the different groups. Serum al-
bumin was significantly lower in subjects with GFR <
30 mL/min/1.73 m2 as compared to subjects with GFR ≥
60 mL/min/1.73 m2 (Table 2).
Urinary output of p-cresol. The 24-hour urinary p-
cresol output in the three study groups is illustrated in
Figure 3A and Table 2. Groups B and C subjects had
significantly increased urinary p-cresol output as com-
pared to subjects from group A. After normalization for
dietary protein intake, an even more pronounced step-
wise increase along with renal function impairment was
observed (Fig. 3B) (Table 2). After stratification for age,
the differences in urinary p-cresol output, and urinary
p-cresol/urea nitrogen ratio remained statistically signif-
icant (P = 0.0021, P = 0.0004, respectively).
Correlations
A significant positive correlation was observed be-
tween 13C protein breath test–derived parameters and
GFR (%max r = 0.399, P < 0.0001; %cumend r = 0.347,
P = 0.0007) (Fig. 4). A significant inverse relationship
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Table 2. Urinary output of p-cresol and urea nitrogen
Group A Group B Group C
(GFR ≥ 60 mL/min/1.73 m2) (GFR 59 to 30 mL/min/1.73 m2) (GFR < 30 mL/min/1.73 m2)
Number 44 29 49
Age years 35.5 (20–70) 69 (24–83)a 68 (35–92)a
Male/female 17/27 17/12 27/22
Body weight kg 64.5 (47.0–116.0) 69.3 (45.6–108.4) 67.7 (44.1–101.6)
Body mass index kg/m2 22.21 (18.03–38.41) 25.66 (18.27–37.07)a 24.71 (15.63–30.75)
Serum urea nitrogen mg/dL 30.0 (15.0–75.0) 50.0 (25.0–118.0)a 122.5 (45.0–234.0)a,b
Serum creatinine mg/dL 0.93 (0.73–1.38) 1.50 (1.00–2.13)a 3.20 (1.78–8.91)a,b
Glomerular filtration rate mL/min/1.73 m2 86.35 (60.36–111.18) 46.11 (31.82–58.74)a 19.49 (7.04–29.93)a,b
Serum albumin g/L 41.7 (31.2–50.0) 40.95 (21.8–48.1) 40.6 (24.6–46.0)a
Urinary p-cresol mg/24 hours 28.65 (0.33–381.11) 50.67 (7.32–231.93)a 54.88 (5.37–417.91)a
Urinary urea nitrogen g/24 hours 20.05 (9.34–36.05) 15.7 (5.2–40.1)a 16.0 (3.09–34.3)a
Urinary p-cresol/urea nitrogen ratio 1.38 (0.02–14.60) 3.23 (0.72–14.45)a 4.19 (0.41–30.19)a
Data are expressed as median and range. Differences between groups were evaluated by Kruskal-Wallis test followed by post hoc pair-wise comparisons.










































































Fig. 3. Urinary output of p-cresol. (A) The median values of urinary
p-cresol output (mg/24 hours) in the three study groups. (B) The me-
dian values of the urinary p-cresol (mg/24 hours)/urinary urea nitrogen
(g/24 hours) ratio. ∗P < 0.05 vs. group A.
was found between urinary p-cresol output (r = −0.229,
P = 0.007) and urinary p-cresol/urea nitrogen ratio (r =
−0.310, P = 0.0003) on the one hand and GFR on
the other. Urinary p-cresol output was positively corre-
lated with urinary urea nitrogen output (r = 0.193, P =
0.028). Similar relationships were found, when the analy-
sis was confined to the CRF patients only: %max vs. GFR
















Fig. 4. %cumend of the 13C protein breath test vs. glomerular fil-
tration rate (GFR) (mL/min/1.73 m2). r is Pearson correlation
coefficient.
P = 0.035), and urinary p-cresol/urea nitrogen ratio vs.
GFR (r = −0.233, P = 0.023). Serum albumin was posi-
tively correlated with parameters of protein assimilation
(%max r = 0.399, P = 0.0002; %cumend r = 0.408, P =
0.0001) and inversely with urinary output of p-cresol (r =
−0.186, P = 0.034). There was a positive correlation of
albumin with GFR (r = 0.239, P = 0.002) and BMI (r =
0.423, P < 0.0001). Urinary urea nitrogen output was
positively correlated with GFR (r = 0.301, P = 0.0005)
(Table 3). No correlations were found between age and
13C protein breath test–derived parameters (%max r =
−0.080, P = 0.448; %cumend r = −0.009, P = 0.931), nor
between age and urinary p-cresol output (r = 0.159, P =
0.060).
DISCUSSION
Information on the efficiency of protein assimilation in
CRF patients is scarce, most probably due to the lack of
an easy and reliable measuring technique. In the present
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Table 3. Correlations
Urinary Urinary urea p-cresol/urea Serum
%cumend %max p-cresol nitrogen nitrogen ratio albumin BMI GFR
%cumend 1 0.941c 0.160 −0.147 0.110 0.408c 0.203 0.347c
%max 1 0.095 −0.137 0.060 0.399c 0.164 0.399c
Urinary p-cresol 1 0.193a 0.837c −0.186a −0.107 −0.299b
Urinary urea nitrogen 1 −0.171 0.109 −0.008 0.301c
p-cresol/urea nitrogen ratio 1 −0.159 −0.087 −0.310c
Serum albumin 1 0.423c 0.239c
BMI 1 −0.073
GFR 1
Abbreviations are: BMI, body mass index; GFR, glomerular filtration rate. Pearson correlation coefficients (r) for 13C protein breath test parameters, urinary output
of p-cresol, and urea nitrogen, serum albumin, BMI, and renal function.
aP < 0.005; bP < 0.01; cP < 0.005.
study, protein assimilation was evaluated by means of a
recently developed and validated 13C protein breath test
[19, 21, 26, 27] and by quantification of the urinary out-
put of p-cresol [19, 21]. Our breath test data provide evi-
dence that protein assimilation is impaired in uremia. The
mean 13CO2 excretion curve, expressed as %dose/hour,
was flattened in subjects with an estimated GFR <
30 mL/min as compared to subjects with GFR ≥ 60 mL/
min and mathematically derived parameters of protein
assimilation (%cumend, %max) were significantly lower in
the former group (Fig. 1) (Table 1). Moreover, a positive
relationship between these parameters and renal function
was demonstrated (Fig. 4) (Table 3). We recognize that
the appearance of 13CO2 in breath is not only influenced
by determinants of the protein assimilation process, but
also by factors related to the postabsorptive metabolism
(oxidation rate, bicarbonate pool retention). In order to
ascertain the validity of the 13C breath test as a tool for the
evaluation of protein assimilation in uremia, it was aimed
to minimize metabolic interference by excluding patients
with diabetes mellitus, hepatic failure, and/or metabolic
acidosis. These conditions have previously been shown
to interfere with protein metabolism [10–12, 28–33]. In
the absence of overt metabolic acidosis, uremic patients
show normal adaptive responses to a low-protein diet [11,
34–36]. One of these responses consists of a reduction
in irreversible oxidation of essential amino acids, which
would result in a lower 13CO2 excretion derived from
administered 13C-leucine. However, major differences in
protein intake as assessed by urinary urea nitrogen out-
put [24] were not found between the different groups in
this part of the study. Furthermore, mean 13CO2 excre-
tion curves, obtained after intraduodenal instillation of
a standard 13C-leucine solution, did not differ between
groups, suggesting that the observed differences in 13C
protein breath test results merely reflect impaired protein
digestion in uremia rather than differences in absorption
and/or postabsorptive metabolism.
p-Cresol is a unique bacterial fermentation metabo-
lite of tyrosine in the colon. Since most of the p-cresol
produced in the colon is urinarily excreted, it can be
assumed that in a steady-state situation, urinary output
reflects colonic generation [19–21]. Significantly higher
urinary p-cresol excretion was seen in subjects with
GFR < 60 mL/min/1.73 m2 than in subjects with GFR ≥
60 mL/min/1.73 m2 (Fig. 3A) (Table 2). In agreement with
a previous study, the colonic production of p-cresol was
shown to correlate with the dietary protein intake [21]
(Table 4). However, after normalization for dietary pro-
tein intake, the stepwise increase of urinary p-cresol out-
put along with renal function impairment was even more
striking (Fig. 3B) (Table 2). These observations support
the hypothesis of impaired protein assimilation in ure-
mia. We also analyzed the data of the CRF patients sep-
arately. The results of this analysis were almost identical
to those obtained in the entire study population. Over-
all, the correlation data indicate that the efficiency of
protein assimilation declines along with renal function
impairment. Whether protein assimilation is impaired in
patients with incipient nephropathy remains an unan-
swered question. Although our study was not designed to
resolve this issue, a reanalysis of the urinary data for this
purpose at least does not support this hypothesis (data not
shown).
Our findings are not that surprising considering the
broad range of uremia-related gastrointestinal abnor-
malities reported in literature, including gastrointestinal
motility disorders [37–41], small bowel bacterial over-
growth [42, 43], gastric hypochlorhydria [26, 37, 44], and
uremic pancreopathy [44–52]. Each of them could theo-
retically disturb protein digestion and/or absorption. The
lack of a correlation between the 13C protein breath test
results and the urinary output of p-cresol (Table 3), in
our opinion, does not question our conclusions but rather
reflects the fact that urinary output of p-cresol is deter-
mined not only by protein assimilation efficiency. Urinary
output of p-cresol is known to be influenced by dietary
protein intake. Both quantity and quality of the protein
may be important in this regard [21, 53]. We normal-
ized our data for the quantity of dietary protein. Since
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subjects were on a free diet, however, we were not able
to evaluate the possible impact of qualitative differences.
Other factors involved are characteristics of the bacte-
rial flora and colonic transit time [54, 55]. In contrast, the
breath test results are not influenced by these factors and
hence only depend on the efficiency of the assimilation
process.
As in other studies [1–6], we found a positive associ-
ation between the nutritional parameter serum albumin
and GFR. Of interest were the correlations found be-
tween serum albumin and protein assimilation param-
eters (%cumend, %max, and urinary output of p-cresol).
These correlations were independent of C-reactive pro-
tein levels (multivariate regression analysis, data not
shown). Although there was a trend for an association
with BMI, statistical significance was not reached, prob-
ably due to small power. The findings strengthen the
hypothesis of impaired small intestinal protein assimi-
lation as a contributing factor to malnutrition in uremia.
Although it was shown that protein requirements of non-
dialyzed CRF patients do not differ from those of nor-
mal subjects [11, 36], impaired protein assimilation will
at least make them more vulnerable in case of lower di-
etary protein intake due to intercurrent illnesses. More-
over, it will probably aggravate the detrimental effects of
inflammation and metabolic acidosis.
Further studies are required to confirm our data and
to elucidate the underlying pathogenetic mechanisms.
CONCLUSION
Our data provide for the first time evidence that pro-
tein assimilation is impaired in uremia. Impaired protein
assimilation might, besides other well-known factors as
lower dietary protein intake, metabolic acidosis, inflam-
mation, and resistance to anabolic hormones, contribute
to protein malnutrition in uremia. Furthermore, our find-
ings underscore the role of the colon in the uremic syn-
drome, since bacterial fermentation metabolites, such as
p-cresol, are increasingly recognized as important ure-
mic toxins [56]. This study demonstrates that besides a
decline in renal clearance an increased colonic produc-
tion may contribute to the accumulation of these toxins in
uremia.
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